Navigation Links
CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
Date:5/26/2009

VIENNA, Va. May 26 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it is developing an immune-based treatment for the "swine flu and related H1N1" flu viruses, utilizing its proprietary L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology. The Company plans to utilize the expertise and knowledge it has gained from developing protective and therapeutic vaccines utilizing L.E.A.P.S. to develop a therapeutic treatment based upon the technology for people infected with the swine and H1N1 flu viruses. CEL-SCI has already commenced pre-clinical testing.

Previously, CEL-SCI announced that its CEL-1000 peptide, which is derived from the L.E.A.P.S. technology, showed adjuvant activity when used with a peptide based malaria vaccine and a DNA based malaria vaccine in animal challenge studies as part of a Cooperative Research arrangement with the Naval Medical Research Center, Silver Spring, MD. In both cases, the addition of CEL-1000 to the vaccines resulted in significant increases in the protection of the animals. In addition, several different L.E.A.P.S. conjugates induced protection and/or improvement in diseases as diverse as rheumatoid arthritis, malaria, TB and herpes simplex viruses. This shows that the L.E.A.P.S. technology can be successfully applied to many different diseases and these results further suggest that L.E.A.P.S. has the potential to be used either alone as a therapy or as an adjuvant to vaccines under development for the treatment of H1N1 related flu viruses. Adjuvants are designed to improve the effectiveness of vaccines.

"We believe that our L.E.A.P.S. technology platform offers strong potential to address the current swine and H1N1 flu viruses," said Dr. Daniel Zimmerman of CEL-SCI, the inventor of the technology. "With the swine flu currently cr
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
2. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
3. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
4. CEL-SCI Corporation Announces 2008 Financial Results
5. CEL-SCI Corporation Releases Letter to Shareholders
6. Updated Pictures of CEL-SCI Manufacturing Facility Available Online
7. CEL-SCI Takes Delivery of New Manufacturing Facility
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
10. CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter
11. CEL-SCI to Present at the Noble Financial Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... MA & Budapest, Hungary (PRWEB) April 30, 2015 ... only web-based electronic lab notebook with integrated protocols ... in providing chemistry software solutions and consulting services ... led to the development of Labguru’s newest feature: ... set of deep domain features for biologists, bio-chemists, ...
(Date:4/30/2015)... Calif. , April 30, 2015  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, today announced that ... on Thursday, May 7, 2015 after the close of ... conference call and webcast on Thursday, May 7, 2015 ... discuss the results and recent corporate developments. ...
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Fleur’s introduces CC ... the benefits of makeup, skin care and solar ... cream is designed with specific complexion-correcting pigments to ... complexion and a healthy glow. Far more than ...
(Date:4/30/2015)... California (PRWEB) April 30, 2015 ... 2015 PharmaSUG Annual Conference held in Orlando, ... of Staffing Solutions along with Leslie Kolman, Manager of ... the latest Clinovo news at Booth #17. , ... Annual Conference again this year”, Says Trisha Heredia, Senior ...
Breaking Biology Technology:Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3
... talks are among those that will be presented by ... Laboratory at the American Physical Society meeting, March 10-14, ... Please note that the content of each talk is ... below. All of the research described below was funded ...
... Medco Health,Solutions, Inc. (NYSE: MHS ) announced ... principal amount of 6-1/8 percent senior notes due March,15, ... percent,senior notes due March 15, 2018 in an underwritten ... Securities LLC and Barclays,Capital Inc. are acting as representatives ...
... 14 at 8:00 a.m. PDT ... ... (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing products targeting the ... December 31, 2007., "Our achievements in 2007 have advanced our partnered ...
Cached Biology Technology:News from the March 2008 American Physical Society Meeting 2News from the March 2008 American Physical Society Meeting 3News from the March 2008 American Physical Society Meeting 4News from the March 2008 American Physical Society Meeting 5Medco Issues $1.5 Billion of Senior Notes 2Medco Issues $1.5 Billion of Senior Notes 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... are improving the taste, appearance and nutritional content of ... grow to $6 billion by 2017, according to a ... (IFT) Annual Meeting & Food Expo in Chicago. ... an immune disorder triggered by the ingestion of gluten ...
... tissue sustains irreparable damage in the wake of a ... and the cardiac muscle contains few stem cells, the ... fibrotic and cannot contract properly. In their search ... been exploring cardiac "patches" that could be transplanted into ...
... to cancer and other diseases, genetic testing, infectious proteins ... topics internationally renowned speakers will tackle at The EMBO ... from 21-24 September 2013. Sir Michael Stratton, Director ... Executive Officer of deCODE Genetics, and Thijn Brummelkamp, Group ...
Cached Biology News:New technologies and ingredients provide better options for gluten-free eating 2A heart of gold 2Anne Glover and Sir Michael Stratton to meet the press at The EMBO Meeting 2013 in Amsterdam 2
... of Class II Biological Safety Cabinets ... to the world's highest safety standards. ... cabinets cannot be adjusted out of ... noise and arm rest ensure safety ...
... recently launched a custom synthesis service ... Thermos siRNA molecules are: Composed ... DNA bases overhang at the 3-terminus ... fully deprotected and ready-to-use. Simply ...
... orbital shaker stands both present ... ergonomic height, and help protect ... welded tubular steel, these heavy-duty ... the weight and minimize the ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
Biology Products: